Market Introduction
North America is the largest market for point of care diagnostics. The region includes US, Canada, and Mexico. The growth of the North America market is characterized by the growing prevalence of infectious diseases, government support for advanced diagnostics kits and instruments, and increasing efforts in R&D activities undertaken by the market players operating in the market. In addition, technological advancements in the diagnosis industry is likely to be a major growth stimulator for the point of care diagnostics market in North America. In US, Centers for Medicare and Medicaid Services (CMS) directs Medicare, which is a federal program for adults aged above 65 and people with disabilities, and it works along with state governments. CMS maintain both Medicaid and the Children’s Health Insurance Program (CHIP), an assembly of federal-state programs for various low-income people. Medicare delivers coverage for physician services, hospitalization, and a voluntary supplementary program, prescription drugs. Additionally, the presence of top revenue-generating medical device companies that can invest a significant amount in R&D supports the market growth as these companies manufacture innovative medical devices.
In case of COVID-19, North America is highly affected specially the US. The outbreak of the COVID-19 pandemic situation shown some favorable scenario for players operating in the point of care diagnostics market. Significant population of North America is infected with coronavirus. For instance, the US is a highly affected country in the North American regions. The effect of the corona is mild in adults; however, it is adverse in older people. The infection of corona among older people has resulted in severe complications and has accounted for a good number of deaths in the country. But during the pandemic situation, life science companies engaged in development of novel drugs for the treatment of life threaten diseases. In addition, increasing demand for rapid testing equipment is also playing a prominent role in the growth of the North America point of care diagnostics market. Furthermore, due to the rising numbers of COVID-19 population has positive impact on the adoption of point of care diagnostic kits. This adoption is boosting new product development and launches in the market. For instance, in July 2020, Eurofins U.S. Clinical Diagnostics has announced the availability of its pooled PCR test to detect SARS-CoV-2, which would substantially lower the cost per PCR test for clients. Moreover, in March 2020, Abbott received FDA approval for its molecular point-of-care test for the diagnosis of COVID-19. The test is capable to deliver positive results in five minutes and negative result in less than fifteen minutes. Such product launches are expected to accelerate the growth of the North America point of care diagnostics market.
Market Overview and Dynamics
The North America point of care diagnostics market is expected to grow from US$ 16,612.40 million in 2021 to US$ 38,702.11 million by 2028; it is estimated to grow at a CAGR of 12.8% from 2021 to 2028. Various conferences and events are held to make people aware about devices and give overview of the common key principles that should be applied when establishing and maintaining point-of-care testing (POCT) services. Participants in these conferences/events can utilize these learnings to develop a framework for introducing POCT for a specific clinical need relevant to their family practice. In June 2019, SELECTBIO held the Point-of-Care, Biosensors & Mobile Diagnostics conference. The Emerging Trends and Themes in Point-of-Care Diagnostics and Mobile Diagnostics, Commercialization of Microfluidic Devices for Point-of-Care Applications, and Paper-based Analytical Devices for the Diagnosis and Monitoring of Infectious Diseases at the Point of Care were the major topics covered in this conference. So, burgeoning number of conferences and events is expected to escalate the market growth.
Key Market Segments
In terms of product, the glucose monitoring products segment accounted for the largest share of the North America point of care diagnostics market in 2020. In terms of prescription mode, the prescription-based testing segment held a larger market share of the North America point of care diagnostics market in 2020. Further, the professional diagnostic centers segment held a larger share of the North America point of care diagnostics market based on end user in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the North America point of care diagnostics market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; BD; bioMerieux SA; BIO-RAD LABORATORIES INC.; Danaher; F. HOFFMANN-LA ROCHE LTD.; Johnson and Johnson Services, Inc.; Nova Biomedical; Polymer Technology Systems, Inc. (PTS); and Siemens AG.
Reasons to buy report
- To understand the North America point of care diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America point of care diagnostics market
- Efficiently plan M&A and partnership deals in North America point of care diagnostics market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America point of care diagnostics market
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
North America Point of Care Diagnostics Market Segmentation
North America Point of Care Diagnostics Market - By Product
- Glucose Monitoring Products
- Infectious Disease Testing Products
- HIV Testing
- Influenza Testing
- Sexually Transmitted Disease (STD) Testing
- Hepatitis C Testing
- Healthcare-Associated Infection (HAI) Testing
- Tropical Disease Testing
- Respiratory Infection Testing
- Other Infectious Disease Testing
- Cardiometabolic Testing Products
- Pregnancy and Fertility Testing Products
- Coagulation Testing Products
- Tumor/Cancer Marker Testing Products
- Cholesterol Testing Products
- Urinalysis Testing Products
- Hematology Testing Products
- Other POC Products
North America Point of Care Diagnostics Market - By Prescription Mode
- Prescription-Based Testing
- OTC Testing
North America Point of Care Diagnostics Market - By End User
- Professional Diagnostic Centers
- Hospitals
- Clinical Laboratories
- Outpatient Healthcare
- Ambulatory Care Settings
- Home Care
- Research Laboratories
- Others
North America Point of Care Diagnostics Market - By Country
- US
- Canada
- Mexico
North America Point of Care Diagnostics Market - Company Profiles
- Abbott
- BD
- bioMerieux SA
- BIO-RAD LABORATORIES INC.
- Danaher
- F. HOFFMANN-LA ROCHE LTD.
- Johnson and Johnson Services, Inc.
- Nova Biomedical
- Polymer Technology Systems, Inc. (PTS)
- Siemens AG
North America Point of Care Diagnostics Market Strategic Insights
North America Point of Care Diagnostics Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 16,612.40 Million |
| Market Size by 2028 | US$ 38,702.11 Million |
| CAGR (2021 - 2028) | 12.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
North America Point of Care Diagnostics Market Country and Regional Insights